Intravenous induction followed by subcutaneous maintenance therapy with guselkumab has shown significant improvements in clinical and endoscopic outcomes for adults with moderately to severely active Crohn's disease at 48 weeks. In two phase 3 trials (GALAXI-2 and GALAXI-3), involving over 1,000 participants across 40 countries, guselkumab surpassed placebo and provided superior results compared to ustekinumab. Most patients achieving clinical remission were corticosteroid-free for over 90 days, with noted serious adverse events but no deaths reported.

Source: The Lancet